Open AccessAlogliptin – the new member of DPP-4 inhibitors class
Author(s) -
Н. А. Петунина,
Анна Леонтьевна Терехова
Publication year - 2014
Publication title -
ožirenie i metabolizm
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.154
H-Index - 5
eISSN - 2306-5524
pISSN - 2071-8713
DOI - 10.14341/omet2014425-31
Subject(s) - alogliptin , pioglitazone , glibenclamide , metformin , type 2 diabetes mellitus , medicine , pharmacology , type 2 diabetes , drug class , diabetes mellitus , insulin , endocrinology , drug , sitagliptin
This review presents data on the efficacy and safety of alogliptin, a new representative of the DPP-4 inhibitors, in adult patients with type2 diabetes mellitus (DM type 2) as monotherapy or in combination with metformin, pioglitazone, glibenclamide and insulin.